United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix, Inc. to Host an Investor Conference Call to Discuss its Nellix® Endovascular Aneurysm Sealing System Presentation at the Society of Vascular Surgery Annual Meeting on June 3, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Dr. Jeffrey Carpenter's submission "Refinement of the IFU for the Nellix® System for Endovascular Aneurysm Sealing Based Upon Outcomes
View HTML
Toggle Summary Endologix, Inc. to Announce First Quarter 2017 Financial Results on May 4, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2017 after the market close on Thursday, May 4, 2017 .
View HTML
Toggle Summary Endologix Enters into $170 Million Credit Facility with Deerfield Management
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into an agreement with Deerfield Management ("Deerfield"), a leading healthcare investment organization, to provide Endologix
View HTML
Toggle Summary Endologix, Inc. Announces Enrollment of First Patients in ELEVATE IDE Clinical Study
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patients were treated in the E xpanding Patient Applicability with Po l ymer S e aling O vat ion Alto St e nt Graft (ELEVATE) IDE
View HTML
Toggle Summary Endologix, Inc. to Present at the Oppenheimer 27th Annual Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott , Chairman and Chief Executive Officer, will present at the Oppenheimer 27 th Annual Healthcare Conference at 8:35 a.m.
View HTML
Toggle Summary Endologix Reports Results for the Fourth Quarter and Full Year 2016
IRVINE, Calif. , Feb. 22, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2016 . John McDermott , Endologix Chief Executive Officer,
View HTML
Toggle Summary Endologix Completes Patient Enrollment in the Ovation® LUCY Study
First Prospective Study Evaluating EVAR in a Female Population
View HTML
Toggle Summary Endologix to Report Fourth Quarter and Full Year 2016 Financial Results on February 22, 2017
IRVINE, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2016 financial results, which will take place on Wednesday,
View HTML
Toggle Summary Endologix Announces Appointment of Dan Lemaitre as Chairman of the Board
John McDermott to Continue as Chief Executive Officer IRVINE, Calif. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that its Board of Directors has elected to separate the positions of Chairman
View HTML
Toggle Summary Endologix to Present at Leerink Partners 6th Annual Global Healthcare Conference
IRVINE, Calif. , Feb. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Vaseem Mahboob , Chief Financial Officer, is scheduled to present at Leerink Partners 6 th Annual Global Healthcare Conference
View HTML
Toggle Summary Endologix Announces Reinstatement of CE Mark for AFX® and AFX2 Endovascular AAA Systems
IRVINE, Calif. , Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that it received notice from its Notified Body in the European Union that the CE Mark for the AFX® and AFX2 Endovascular AAA
View HTML
Toggle Summary Positive Three-Year Results from the Ovation® European Post Market Registry Presented at 2017 LINC Symposium
IRVINE, Calif. , Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive 3-year clinical data from the Ovation European Post Market Registry at the 2017 Leipzig Interventional
View HTML
Toggle Summary Endologix Resumes Shipments of All Sizes of AFX®2 Endovascular AAA Systems
Appoints Laura Nagel as Vice President, Global Quality
View HTML
Toggle Summary Endologix to Present at the 35th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, are scheduled to present at the 35 th
View HTML
Toggle Summary Endologix Provides Physicians with Updated Information about the AFX® Endovascular AAA System
IRVINE, Calif. , Dec. 30, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today issued a letter to physicians with updated information about the AFX® Endovascular AAA System .
View HTML